Page 25 - Solid Tumors News Today

The FDA has accepted for review a biologics license application seeking the approval of tislelizumab for use in the frontline treatment of patients with unresectable, recurrent, locally advanced or metastatic esophageal squamous cell carcinoma.

PredicineBEACON™ and PredicineWES+™ were used to detect and monitor a diverse spectrum of genomic alternations and emerging resistance mechanisms in...

HAYWARD, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine

European Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma U.S. FDA accepts Biologics License Application in first-line advanced ESCC ...

19.09.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA ... Seite 1

Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide TEVIMBRA is the cornerstone of BeiGene’s solid tumor portfolio,...

FCS Director of Drug Development Manish Patel, MD Co-Authors BothFORT MYERS, Fla., Sept. 15, 2023 /PRNewswire/ -- Florida Cancer Specialists & Res...

A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of erdafitinib for the treatment of adult patients with locally advanced, unresectable or metastatic urothelial carcinoma harboring susceptible FGFR3 alterations who experienced disease progression during or following at least 1 line of therapy containing a PD-1/PD-L1 inhibitor.

Marwan G. Fakih, MD, expands on long-term findings from the phase 2/3 PROSPECT trial and how these findings may influence the optimal use of nonoperative management strategies in locally advanced rectal cancer.

Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.